Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2022-01-27 Regulatory Filings
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates announces a new routine customer in Spain using suPARnostic® TurbiLatex for suPAR guided anakinra treatment of patients with COVID-19 disease
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from ViroGates regarding a new customer implementation of their medical technology (suPARnostic) in a Spanish hospital. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate update regarding business operations and product adoption, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2022-01-27 English
ViroGates announces a new routine customer in Spain using suPARnostic® TurbiLatex for suPAR guided anakinra treatment of patients with COVID-19 disease
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from ViroGates regarding a new customer implementation of their medical technology. It follows the standard format of a corporate press release or regulatory announcement. Since it does not fit into specific categories like financial reports, board changes, or shareholder voting, and is a general corporate update, it falls under the 'Regulatory Filings' (RNS) category.
2022-01-27 English
ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakinra treatment of patients with COVID-19 pneumonia
Regulatory Filings Classification · 95% confidence The document is a company announcement from ViroGates regarding a positive opinion from the CHMP of the EMA for a medical treatment (anakinra) that utilizes their suPARnostic technology. It is a standard corporate press release/announcement detailing business developments, clinical trial results, and regulatory progress. It does not fit into specific financial reporting categories like 10-K, IR, or DIV, and is not a report publication announcement (RPA) as it contains the substantive news itself rather than just announcing the availability of a separate report. Therefore, it falls under the general regulatory announcement category.
2021-12-16 English
ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakinra treatment of patients with COVID-19 pneumonia
Regulatory Filings Classification · 95% confidence The document is a company announcement from ViroGates regarding a positive opinion from the EMA's CHMP for a medical treatment. It follows the standard format of a corporate regulatory announcement (RNS), providing details on the news, company background, and contact information. It does not fit into specific categories like financial reports, proxy statements, or audit reports, and serves as a general regulatory disclosure of material information.
2021-12-16 English
ViroGates announces a development, supply and collaboration agreement with Italy-based DIESSE for adaption of suPARnostic® ELISA on the Chorus Trio platform
Regulatory Filings Classification · 95% confidence The document is a company announcement from ViroGates regarding a new development, supply, and collaboration agreement with DIESSE. It details a strategic partnership to adapt a product (suPARnostic ELISA) to a new platform (Chorus Trio). This type of corporate news regarding business operations, partnerships, and strategic collaborations does not fit into specific financial reporting categories like 10-K, ER, or IR, and is best classified as a general regulatory announcement.
2021-12-09 English
ViroGates announces a development, supply and collaboration agreement with Italy-based DIESSE for adaption of suPARnostic® ELISA on the Chorus Trio platform
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a new development, supply, and collaboration agreement between ViroGates and DIESSE. It details the nature of the partnership, the technology involved, and the expected market availability. It does not fit into specific categories like financial reports, board changes, or share transactions. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2021-12-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.